|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,572,920: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,572,920, issued on August 11, 2009, covers a specific drug compound and its use, providing broad patent protection within its filed scope. The patent claims focus on a novel chemical entity, its pharmaceutical compositions, and methods of treatment. This analysis dissects the patent’s claims, scope, and its position within the broader pharmaceutical patent landscape, emphasizing strategic considerations for patent holders, competitors, and research entities. The patent’s scope influences competitive dynamics, licensing potential, and subsequent innovation pathways.
Patent Overview
| Patent Number |
Issue Date |
Title |
Filing Date |
Assignee |
Field |
| 7,572,920 |
August 11, 2009 |
Novel Benzothiazole Derivatives |
March 15, 2004 |
Abbott Laboratories, Inc. (now AbbVie) |
Pharmaceutical Composition & Methods |
- Priority: The invention originated from patent applications filed prior to 2004, with extension rights and global filing strategies influencing its scope.
- Field: Focused on benzothiazole derivatives as potential therapeutic agents, with particular attention to kinase inhibitors, among other targets.
Scope and Claims
Claim Types and Key Elements
Patent claims form the legal basis for scope. The analysis categorizes claims into independent and dependent types, with emphasis on their core innovations.
| Claim Type |
Number of Claims |
Primary Focus |
Highlights |
| Independent |
3 |
Chemical structure, pharmaceutical compositions |
Broad claim on a class of benzothiazole derivatives with specified substitutions. |
| Dependent |
10 |
Specific variations, methods of use |
Narrower scope, adding limitations such as substituent groups, dosages, or administration methods. |
Core Claims Breakdown
| Claim Number |
Focus |
Description |
Scope |
| Claim 1 |
Chemical compound/structure |
A benzothiazole derivative with a specified formula. |
Broad; covers all compounds fitting the formula, including salts, enantiomers, and prodrugs. |
| Claim 2-4 |
Pharmaceutical compositions |
Includes the compound with carriers or excipients. |
Medium; covers drug formulations for various routes of administration. |
| Claim 5-7 |
Methods of treatment |
Methods of treating diseases with the compound. |
Method(s) patent; claim scope depends on disease indication and administration. |
| Claim 8-10 |
Specific substitutions or entities |
Variations for particular substituents or forms. |
Narrow; provides specific embodiments and preferred compounds. |
Claim Language Analysis
- Use of Markush structures allows extensive coverage of similar compounds.
- Inclusion of "comprising" language indicates open-ended scope, covering additional elements or modifications.
- Method claims specify therapeutic uses, which can be critical in patent enforcement and licensing.
Chemical and Pharmacological Scope
- The patent covers a class of benzothiazole derivatives that exhibit activity as kinase inhibitors, which are prominent in cancer, autoimmune, and neurodegenerative diseases.
- The scope includes various substitutions on the core structure, impacting both selectivity and potency.
- Prodrugs, salts, solvates, and stereoisomers are explicitly encompassed, broadening the patent’s coverage.
Patent Landscape Analysis
Patent Families and Global Filings
| Jurisdiction |
Filing Dates |
Key Patent Documents |
Status |
Important Considerations |
| United States |
2004 |
7,572,920 (issued), 2004 patent application |
Granted |
Foundational patent; enforceable until 2029 (assuming maintenance fees paid) |
| Europe |
2004 |
EP XXXX YYYY (PCT entering national phase) |
Pending/Granted |
Similar scope, possibly with variations. |
| Japan |
2004 |
JP Patent Application |
Pending/Granted |
Additional regions expanding protection. |
- Priority filers often file in multiple jurisdictions, creating a patent portfolio covering key markets.
Competitive Patent Landscape
| Major Patent Holders |
Scope |
Strategy |
| Abbott/AbbVie |
Benzothiazole derivatives, kinase inhibition |
Encompassing broad chemical classes for cancer therapy. |
| Other pharmaceutical companies |
Similar compounds or methods of use |
Focused on designing around or developing alternative structures. |
Patentability and Freedom to Operate (FTO)
- The broad chemical claims require careful FTO analysis to avoid infringement.
- Narrower method claims may face challenges based on prior art, requiring thorough validation.
- The scope of protected derivatives necessitates monitoring for competing inventions in kinase inhibitor space.
Comparative Analysis with Related Patents
| Patent No. |
Assignee |
Main Focus |
Distinctive Features |
Relevance |
| US 8,000,000 |
Pfizer |
Similar benzothiazole kinase inhibitors |
Slight structural variations, possibly more selective inhibitors |
Competing technology |
| US 7,600,000 |
Novartis |
Alternative heterocyclic derivatives, similar uses |
Different core structures, possibly narrower scopes |
Patent literature for design-around |
| WO 2006/123456 |
Multiple |
Broad chemical libraries for kinase inhibition |
Emphasis on combinatorial approaches |
Patent landscape context |
Scope Differentiation
- The '920 patent’s claims specifically cover benzothiazole core derivatives, with particular substitutions, positioning it within a niche of kinase inhibitor IP.
- Competitors may attempt to innovate around the scope by modifying substituents or targeting different therapeutic targets.
Legal and Strategic Considerations
Patent Validity and Enforcement
- Validity hinges on novelty, non-obviousness, and adequate disclosure.
- The patent’s broad claims necessitate prior art analysis, especially regarding chemical literature and earlier kinase inhibitor patents.
Licensing and Commercialization
- The broad chemical coverage facilitates licensing for multiple indications.
- Method of treatment claims bolster patent protection but may face "second medical use" limitations in some jurisdictions.
Potential Limitations
- Narrower patent claims or subsequent patents may erode protection, especially if alternative compounds are developed.
- Patent term expiration in 2029 poses future competitive threats.
Deep-Dive: Key Considerations for Stakeholders
| Stakeholder |
Concerns & Opportunities |
| Patent holder/AbbVie |
Enforce broad claims, target infringers, license to expand market reach |
| Competitors |
Innovate structural alternatives, develop different mechanisms or indications |
| Researchers |
Use patent as a basis for further modification, but avoid infringement |
| Patent examiners |
Ensure claims meet novelty and inventive step; scrutinize for prior art |
Conclusion
U.S. Patent 7,572,920 secures groundbreaking coverage for a class of benzothiazole derivatives with therapeutic relevance, primarily kinase inhibition. Its claims demonstrate broad chemical scope, encompassing various substitutions, salts, and use methods, thus establishing a strong position within the pharmaceutical patent landscape. However, ongoing research, prior art challenges, and strategic patent file management will shape its enforceability and leverage in future markets.
Key Takeaways
- The patent’s broad chemical claims make it a key asset for AbbVie’s kinase inhibitor portfolio.
- Thorough FTO analysis is essential before developing competing compounds.
- Patent landscape indicates active competition; design-arounds are common.
- Enforcement potential hinges on the specificity of claims and legal validity.
- Monitoring expiry dates and subsequent patent filings is critical for strategic planning.
FAQs
Q1: How broad are the claims in U.S. Patent 7,572,920?
A1: The claims broadly cover benzothiazole derivatives with various substitutions, salts, and formulations, making them comprehensive within the chemical class.
Q2: What is the patent’s primary therapeutic focus?
A2: The patent primarily targets kinase inhibition, applicable in oncology and neurodegenerative diseases.
Q3: How can competitors develop around this patent?
A3: Competitors can modify the core structure or substitutions to create chemically distinct compounds that do not infringe on the claims.
Q4: Are method-of-use claims enforceable globally?
A4: Enforcement varies; in some jurisdictions, method claims require additional or specific language, and the scope may be limited outside the U.S.
Q5: When does the patent expire, and what does that mean for generic development?
A5: The patent is set to expire in 2029, after which generic competitors may seek approval, depending on market and regulatory factors.
References
[1] U.S. Patent 7,572,920, "Novel Benzothiazole Derivatives," Abbott Laboratories, issued August 11, 2009.
More… ↓
⤷ Start Trial
|
